Utilization of serologic assays to support efficacy of vaccines in nonclinical and clinical trials: Meeting at the Crossroads
- 12 May 2010
- journal article
- research article
- Published by Elsevier BV in Vaccine
- Vol. 28 (29), 4539-4547
- https://doi.org/10.1016/j.vaccine.2010.04.094
Abstract
No abstract availableKeywords
This publication has 93 references indexed in Scilit:
- Analysis of the Fc Gamma Receptor-Dependent Component of Neutralization Measured by Anthrax Toxin Neutralization AssaysClinical and Vaccine Immunology, 2009
- Relative importance of complement-mediated bactericidal and opsonic activity for protection against meningococcal diseaseVaccine, 2009
- Harmonization guidelines for HLA-peptide multimer assays derived from results of a large scale international proficiency panel of the Cancer Vaccine ConsortiumCancer Immunology, Immunotherapy, 2009
- Characterization of Reference Materials for Human Antiserum to Pertussis Antigens by an International Collaborative StudyClinical and Vaccine Immunology, 2009
- Evaluating a surrogate endpoint at three levels, with application to vaccine developmentStatistics in Medicine, 2008
- Testing human sera for antibodies against avian influenza viruses: Horse RBC hemagglutination inhibition vs. microneutralization assaysJournal of Clinical Virology, 2008
- Results and harmonization guidelines from two large-scale international Elispot proficiency panels conducted by the Cancer Vaccine Consortium (CVC/SVI)Cancer Immunology, Immunotherapy, 2007
- Group B Streptococcus: global incidence and vaccine developmentNature Reviews Microbiology, 2006
- Development and Validation of a Fourfold Multiplexed Opsonization Assay (MOPA4) for Pneumococcal AntibodiesClinical and Vaccine Immunology, 2006
- STATISTICAL METHODS FOR ASSESSING AGREEMENT BETWEEN TWO METHODS OF CLINICAL MEASUREMENTThe Lancet, 1986